GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » Other Operating Expense

Elicera Therapeutics AB (OSTO:ELIC) Other Operating Expense : kr21.64 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB Other Operating Expense?

Elicera Therapeutics AB's Other Operating Expense for the three months ended in Jun. 2024 was kr5.84 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 was kr21.64 Mil.

Elicera Therapeutics AB's quarterly Other Operating Expense increased from Dec. 2023 (kr5.22 Mil) to Mar. 2024 (kr5.43 Mil) and increased from Mar. 2024 (kr5.43 Mil) to Jun. 2024 (kr5.84 Mil).

Elicera Therapeutics AB's annual Other Operating Expense increased from Dec. 2021 (kr4.16 Mil) to Dec. 2022 (kr19.36 Mil) but then declined from Dec. 2022 (kr19.36 Mil) to Dec. 2023 (kr17.10 Mil).


Elicera Therapeutics AB Other Operating Expense Historical Data

The historical data trend for Elicera Therapeutics AB's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicera Therapeutics AB Other Operating Expense Chart

Elicera Therapeutics AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
- 0.99 4.16 19.36 17.10

Elicera Therapeutics AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.47 5.15 5.22 5.43 5.84

Elicera Therapeutics AB Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr21.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elicera Therapeutics AB Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Elicera Therapeutics AB Business Description

Traded in Other Exchanges
N/A
Address
Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB Headlines

No Headlines